Anti-SARS-CoV-2 Monoclonal Antibodies in Pediatrics: Statewide Experience in Rhode Island.

BACKGROUND

The pediatric population has suffered COVID-19 infections with measurable morbidity and mortality. Without oral options in those less than 12 years of age, practical treatment in this rapidly evolving disease is necessary. One treatment modality is monoclonal antibodies. Limited information describes the efficacy and safety of anti-SARS-CoV-2 monoclonal antibodies in pediatrics. This is the largest case series addressing efficacy and safety of monoclonal antibodies in this population.

OBJECTIVE

To report patient characteristics, side effects encountered, and hospital admissions or emergency department visits within 30 days following treatment.

DESIGN

This retrospective case series includes high-risk pediatric COVID-19 patients who received monoclonal antibody infusions in a tertiary care center as outpatients between January 2021 and January 2022.

OUTCOMES

There were 108 patients included with seven patients (6.5%) having infusion-related reactions with no other adverse events reported. Following the monoclonal treatment, three patients presented to the emergency department for worsening symptoms, and one patient was admitted to the pediatric ICU for worsening respiratory status. No other admissions or emergency department visits were reported in the one month following the infusion.

CONCLUSIONS

In this case series study, monoclonal antibody infusions were well tolerated.